Nucleic Acid Testing
This article was originally published in The Gray Sheet
Executive Summary
FDA will accept comments on its draft guidance entitled "Application of Current Statutory Authority to Nucleic Acid Testing of Pooled Plasma" until Jan. 25, 2000 according to a Nov. 26 notice in the Federal Register. The guidance seeks public comment on the development and implementation of nucleic acid testing for infectious agents "when such testing is intended for use in blood donor screening and/or manufacturing of blood products"
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.